Daratumumab Cuts Risk for Progression in Multiple Myeloma

WEDNESDAY, May 29, 2019 -- For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published in the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news